Aegerion/Novelion Therapeutics/Amryt Pharma: Represented global biopharmaceutical company Aegerion Pharmaceuticals, Inc., a wholly owned subsidiary of Novelion Therapeutics, in its recapitalization, whereby Amryt Pharma Plc agreed to acquire 100% of Aegerion’s reorganized stock.
Allergan/Pfizer: Represented Morgan Stanley as financial advisor to Allergan in its agreement to combine with Pfizer for an enterprise value of approximately $160 billion.
Aralez Pharmaceuticals: Represented Aralez Pharmaceuticals in the following M&A-related transactions:
- AstraZeneca: Represented Aralez in its acquisition of the U.S. rights to beta-blocker Toprol-XL® from AstraZeneca.
- Merck: Represented Aralez in its acquisition of the U.S. and Canadian rights to cardiovascular drug Zontivity from Merck.
ARIAD Pharmaceuticals/Takeda/Sarissa Capital Management: Represented Sarissa Capital Management, the largest shareholder of ARIAD Pharmaceuticals, in connection with ARIAD’s agreement to be acquired by Takeda Pharmaceutical Company Limited for approximately $5.2 billion.
Auxilium/Endo International: Represented Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, in its proposed $2.6 billion acquisition by Endo International plc for a combination of cash and stock.
Ekkio Capital/Amatasigroup/Eurofins: Represented Ekkio Capital on the pending sale of Amatsigroup to Eurofins, the world leader in bio-pharmaceutical testing and a world leader in analytical services.
Ekkio Capital/Audevard: Represented Ekkio Capital in its acquisition of Audevard, a veterinary pharmaceutical company focused on the equine field.
Melinta Therapeutics/Cempra, Inc.: Represented Melinta Therapeutics, Inc. and Vatera Healthcare partners, Melinta’s majority shareholder, in Melinta’s agreement to merge with Cempra, Inc., forming a leading, vertically integrated commercial-stage anti-infectives company.
Melinta Therapeutics/Infectious Disease Business of The Medicines Company: Represented Melinta Therapeutics, Inc, in its pending acquisition the infectious disease business from The Medicines Company.
Mylan/Pfizer Upjohn: Represented Centerview Partners and PJT Partners as financial advisors to Mylan in its agreement to combine with Upjohn, Pfizer's off-patent branded and generic medicines business, to create a new pharmaceutical company.
NeuroDerm/Mitsubishi Tanabe Pharma Corporation: Represented Centerview Partners, financial advisor to NeuroDerm Ltd, in NeuroDerm’s deal to be acquired by Mitsubishi Tanabe Pharma Corporation for $1.1 billion.
PAI Partners/Ethypharm: Represented PAI Partners in its negotiations to acquire European specialty pharma company Ethypharm from Astorg.
RIEMSER Pharma/Intrapharm Laboratories: Represented RIEMSER Pharma GmbH in its acquisition of British specialty pharmaceutical company Intrapharm Laboratories Ltd.
RIEMSER Pharma/Keocyt: Advised RIEMSER Pharma GmbH in its acquisition of French specialty pharmaceutical company Keocyt.
Sagard/Sterimed: Represented Sagard in its acquisition of Sterimed, a leading manufacturer of sterile packaging for the pharmaceutical industry, from Meeschaert Capital Partners.
Salix Pharmaceuticals/Valeant Pharmaceuticals: Represented Centerview Partners as financial advisor to Salix Pharmaceuticals, a leader in the gastrointestinal market, in its agreement to be acquired by Valeant Pharmaceuticals for a total enterprise value of approximately $15.8 billion.
Sanofi-Aventis/Hoechst AG: Represented Sanofi-Aventis, the world’s largest pharmaceutical company, in its mandatory offer to shareholders of Hoechst.
Tesaro/GlaxoSmithKline: Represented Centerview Partners as financial advisor to oncology-focused biopharmaceutical company Tesaro in its acquisition by GlaxoSmithKline for $5.1 billion.
Vatera/CVC/Alvogen: We represented Vatera Healthcare Partners as part of the investment consortium led by CVC Capital Partners in the acquisition of a controlling stake in Alvogen, a high-growth pharmaceutical company, from Pamplona Capital Management.
Voalte/Hill-Rom: Represented Voalte, a pioneer and leader in real-time, mobile healthcare communications, in its sale to global medical technology company Hill-Rom for $180 million.
Warburg Pincus: Advised Warburg on numerous M&A-related transactions, including its investments in the following pharmaceutical companies:
- JHP Pharmaceuticals: Represented Warburg in connection with the approximately $490 million sale of JHP Pharmaceuticals, LLC to Par Pharmaceutical Companies.
- The Medicines Company: Advised Warburg in connection with its investment in The Medicines Company, a provider of cost-effective acute care products.
WuXi/Management-Led LBO: Represented the Special Committee of the Board of Directors of WuXi PharmaTech Inc. in its $3.3 billion management-led leveraged buyout, one of the largest going private transactions of a Chinese-based, U.S. listed company.